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Blood—membrane interaction in hemodialysis leads to increased
cytokine production
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Blood—membrane interaction in hemodialysis leads to increased
cytokine production. Recently much interest has been focused on the
role of immunoregulatory cytokines such as interleukin 1 (IL 1) and
interleukin 2 (IL 2) during the pathogenesis of immunological as well as
inflammatory diseases. Therefore peripheral blood mononuclear cells
(PBMC) of eight patients undergoing hemodialysis (HD) were tested for
IL 1 and IL 2 production. Before starting HD, cytokine production by
PBMC in culture was not altered in comparison to normal healthy
controls, however, a significant increase of IL I and IL 2 production
was observed within the first ND hour which lasted throughout the end
of ND. Moreover direct effects of cellulose membranes on PBMC
cytokine production as well as serum IL I levels have been investi-
gated. Serum IL I levels were already elevated before onset of HD and
increased further during HD. The discrepancy between PBMC IL 1
production and serum IL 1 levels may be due to the diminished
excretion in patients with end—stage renal disease. Since addition of
dialysis membrane particles enhanced monocytes to produce more IL 1
as well as lymphocytes to release more IL 2, a direct stimulatory
membrane effect is postulated. The increased release of immunoreg-
ulatory cytokines may account for some of the pathologic findings
observed during hemodialysis.
Plasma contact with cellophane membrane has been shown to
result in complement activation and leukostasis in the pulmo-
nary vasculature U] leading to the well known granulocytopenia
and hypoxemia [21 in the initial phase of dialysis. Furthermore,
at the same time a significant drop in fibronectin [3] as well as a
rise in temperature later during HD [4] have been described. In
a recent report using cuprophane membranes 15] an increased
T4/T8 ratio has been shown to parallel the initial neutropenia,
which was mainly caused by a decrease of suppressor T8 cells,
and in contrast to the transient nature of the other mentioned
phenomena, persisted throughout the duration of hemodialysis
(ND) for six hours.
In the last years growing interest also has been focused on
immunoregulatory proteins called lymphokines or cytokines.
Upon stimulation monocytes/macrophages secrete interleukin)
(IL 1), a nonspecific immunomodulating factor which activates
a variety of cells involved in inflammation, such as lympho-
cytes, granulocytes and fibroblasts, and in vivo acts as mediator
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of the acute phase response, promotes catabolism of structural
protein matrix and regulates the febrile response [6]. One
important immunological function of IL I is its enhancing effect
on interleukin 2 (IL 2) production by T lymphocytes. IL 2,
formerly called T cell growth factor, provides an essential signal
for the transition of activated T cells from G to the S phase of
the cell cycle [7], but also may activate B lymphocytes, killer
cells and enhance the T cell production of other cytokines, such
as interferon or B cell stimulatory factors (B SF) [8—10].
Since altered production of cytokines such as IL 1 and IL 2
could be responsible for many events and laboratory findings in
HD [II], the capacity of mononuclear cells to release these
factors during HD was tested.
Methods
Patients
Eight patients (pts) with chronic renal failure under intermit-
tent ND (3 X S hr/week) using cellulosic membranes (C-DAK,
Cordis Dow, Miami, Florida, USA; membrane surface 1.8 or
2.5 m2) and acetate baths were studied. Data of patients are
shown in Table 1. Blood was drawn from the arterial site of the
arteriovenous fistula at 0, 30, 60 and 300 minutes. The control
group consisted of 20 healthy volunteers. Informed consent was
obtained from all subjects. All data are given as mean SE and
compared by multiple Student's i-test with the Bonferroni
correction. Differences were considered to be significant when
P was less than 0.05.
Materials
Peripheral blood mononuclear cells (PBMC) were prepared
from peripheral blood obtained from healthy individuals or
patients at various times during HD by gradient centrifugation
on Ficoll Paque (Pharmacia, Upsala, Sweden). The cells were
incubated on plastic petri dishes coated with fetal calf serum
(FCS, Flow Laboratories, Scotland UK) in RPMI 1640 medium
(Grand Island Biological Company, Grand Island, New York,
USA) supplemented with 10% FCS and antibiotics. The non-
adherent cells were harvested, adjusted to 1 X 106 cells/mi in
RPMI 1640 medium containing 1% FCS. Adherent cells were
harvested from the plastic petri dishes with the aid of a rubber
policeman and vigorous pipetting, and adjusted to 1 x 106
cells/ml in RPMI 1640 medium containing 1% FCS. Adherent
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Table 1. Clinical characteristics of the patients on chronic HD
Duration
Patient Age Sex Diagnosisa
of HD
months Therapyb
1 49 m DN 20 1,2
2 49 m CGN 96 1
3 58 m PKD 17 1
4 45 m CGN 8 1
5 43 f DN 25 1,3
6 20 m CGN 3 I
7 25 f CGN 5 1
8 42 m DN 24 1,3
a DN, diabetic nephropathy; CGN, chronic glomerulonephritis;
PKD, polycystic kidney diseaseb
, aluminiumhidroxide + water soluble vitamins + 1,25 dihydro-
cholecaiciferol; 2, oral hypoglycemics; 3, insulin
cells consisted of 95% macrophages and were not different in
patients and controls.
Preparation and assays of IL 1
Adherent cells were cultured in RPM! 1640 with or without
addition of 50 g/ml Silica (Sigma Chemical Company, St.
Louis, Missouri, USA) or 100 g/ml lipopolysaccharide (LPS,
W.E. Coli, Difco, Detroit, Michigan, USA), In some experi-
ments dialysis membranes were mechanically broken up and
layered on the bottom of culture plates before cells were added.
After incubation for 48 hours at 37°C in a 5% CO2 atmosphere
the supernatants were harvested and assayed for IL 1 activity.
The enhancement of mitogen stimulated C3H/He (Institute for
Laboratory Animals, Himberg, Austria) mouse thymocyte pro-
liferation was used for the detection of IL 1 activity as previ-
ously described [121. In brief, thymocytes in suspension culture
were incubated for three days in microculture plates (1.5 X 10
cells/mi) in the presence of 1 jig/ml Concanavalin A and various
dilutions of samples. In order to quantitate the degree of DNA
synthesis, cultures were pulsed with 3H-TdR (0.4 MCi/well) for
the final 16 hours of incubation and harvested as described. In
order to have a more reliable index of IL 1 activity in each
experiment, an IL 1 standard preparation was titrated along
with the unknown samples and units of IL 1 activity were
calculated as described previously [131, using the following
equation:
reciprocal titer of test sample at
30% of maximal cpm of standard
100 x = U/mi
reciprocal titer of 30% of maximal
cpm of standard
One unit (0.01 ng) recombinant IL 1 (Genzyme, Boston, Mas-
sachusetts, USA) was equivalent to 10 U/mi of the IL 1
standard preparation.
Preparation and assay for IL 2
Nonadherent cells were cultured in RPMI 1640 in the pres-
ence of 10 g/m1 Concanavalin A (Con A, Calbiochem, La
Jolla, California, USA) and 10 ng/ml phorbol myristate acetate
(PMA, Sigma, St. Louis, Missouri, USA) at 37°C in a 5% CO2
containing atmosphere. After 48 hours incubation supernatants
were harvested and tested for IL 2 activity as described
previously. Briefly, the samples were tested for their ability to
maintain the growth of an IL 2 dependent murine T-cell line
(CTLL). Cells were adjusted to a density of 1 x io cells/mi in
RPMI 1640 containing 5% FCS. A total of 1 x i04 cells per well
of a 96 well plate were incubated at 37°C in 5% CO2 containing
atmosphere for 48 hours with various concentrations of sample.
Cells were pulsed for the final 16 hours with 3H-TdR and
harvested as described. Thus counts per minute at various
dilutions of test samples were compared to an IL 2 standard and
transformed into units/mi as described previously [141.
Determination of serum IL I activity by HPLC
High—pressure liquid chromatography (HPLC) was per-
formed with a system supplied from LKB (Bromma, Sweden)
using two 2150 pumps, a 2152 system controller, a Rheodyne
7010 injector and a Uvicon 720 LC variable wave length
detector. All manipulations were done at room temperature.
Two hundred tl serum were subjected to a size exclusion
column (BioSil, TSK 125, 300 x 7.5 mm and a BioSil TSK
Guard Column 7.5 x 7.5 mm, Bio Rad Laboratories, Rich-
mond, California, USA). Elution was carried out with phos-
phate buffered saline (PBS), pH 7.2 at a flow rate of 0.8
mi/minute [15]. Fractions containing IL 1 activity between
molecular weight 50 kD and 1 kD [161 were collected as
previously determined. The pooled fractions were filtered ster-
ilized and tested for IL 1 activity as described above. In order
to test for IL 1 inhibiting activity pooled serum fractions were
additionally tested in the presence of 50 U/mI IL 1 (partial-
ly—purified pooled activity of HPLC gel filtration). In some
experiments a monoclonal antibody (Ak 17) against the biolog-
ical active site of IL 1 [17] was tested for its effect on serum IL
1. Anti-IL 1 IgG, 0.25 jig, usually inhibited 70% of the biological
activities of 0.01 ng recombinant human IL lcs or IL 1/3 [18].
Results
Peripheral blood mononuclear cells (PBMC) IL 1 production
IL 1 production by peripheral blood mononuclear—cells from
patients undergoing hemodialysis was evaluated. Culture super-
natants of adherent cells from patients before starting HD
contained normal levels of IL 1 activity. During the course of
HD a significant increase of macrophage IL 1 production was
observed in all patients (Fig. 1). Usually a biphasic pattern of
increased IL 1 production was demonstrated with peak levels
within the first hour and at the end of HD. Addition of Silica,
which is known to increase IL 1 production, further stimulated
adherent cells of patients to produce more IL 1 during HD (Fig.
1). Since the cultures of adherent cells may be contaminated
with some IL 2 producing lymphocytes, and IL 2 like IL I also
enhances the proliferation of thymocytes, the supernatants
additionally were tested for their capacity to induce the prolif-
eration of IL 2 dependent CTLL. However, no detectable
levels of IL 2 activity were present in the adherent cell
supernatants, indicating that the activity measured in the
thymocyte assay is IL 1.
Serum IL 1 activity
It previously has been shown that serum IL 1 usually elutes
between molecular weight 50 kD and I kD [161. Therefore gel
filtration fractions within this molecular weight range were
Table 2. Inhibition of serurn IL 1 activity by rnonoclonal anti-IL 1
lgG
Patient
Serum IL
U/mi
l anti-IL I IgG, jsg/ml
0.5 0.25 0.12
I 12 88b 74b 70b
2 32 75b 63b 31b
3 122 43b 32b NDb
a i U/rnl recombinant IL 1 is equivalent to 10 U/mI of the IL I
standard preparation used in our laboratoryb % inhibition compared to serum IL I activity of each patient
pooled and tested for IL 1 activity. Moreover, a monoclonal
antibody which is known to inhibit the biological activities of
both IL la and IL 1(3 as well as to bind both species of IL 1 [18]
was tested for its effect on serum IL 1. The antibody signifi-
cantly blocked serum IL 1 (50-1 kD) mediated thymocyte—pro-
lileration in a dose dependent manner (Table 2), indicating that
serum IL 1 and rIL 1 a and rIL 1/3 share a similar site which is
responsible for the biological activity.
In addition to PBMC IL 1 production, serum IL 1 activity of
four patients during the course of HD was tested. A significant
increase of already elevated, basal circulating IL 1 activity was
noticed in all patients (Fig. 2). Elevated serum IL 1 levels were
observed within the first hour after starting HD and lasted
throughout the end. In addition to IL 1 sera of HD patients
usually contained an inhibitor of IL 1 activity which eluted
between molecular weight 150 kD and 60 kD (data not shown).
However, a similar IL 1 inhibitor is also found in the sera of
healthy control persons [16].
Peripheral T-lymphocytes derivedIL 2 production
T-lymphocytes from HD patients were tested for their in vitro
IL 2 production. Basal T-cell IL 2 secretion before initiating HD
was within the range observed in normal control persons.
Shortly after connecting patients with end—stage renal failure to
the hemodialyzer a significant rise in IL 2 synthesis was
observed, and IL 2 remained elevated throughout the duration
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of HD (Fig. 3). However, only after 30 minutes the levels were
significantly different from basal levels. Additional stimulation
of T-cells in vitro with Con A and PMA resulted in a further
significant increase of IL 2 secretion at any stage of HD.
However, stimulated IL 2 release was increased significantly
only 30 minutes after starting HD when compared to pre-HD
levels.
In vitro membrane effect on PBMC IL I and IL 2 release
To evaluate a postulated direct effect of the cellulose mem-
branes on PBMC lymphokine production, monocytes or lym-
phocytes obtained from normal healthy volunteers were incu-
bated in the presence of cellulose membrane particles.
Monocyte IL 1 production was significantly elevated when
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Fig. 1. Basal (U) and silica stimulated () PBMC IL 1 production in
healthy controls (NCO) and in patients with ESRD before and during
HD (0, 30, 60 and 300 mm). Unstimulated IL I production is signifi-
cantly elevated at 30 and 300 minutes (P < 0.05); silica stimulated IL I
release only at 300 minutes.
NCO 0 30 60 300
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NCO 0 60 300
Fig. 2. Serum IL 1 activity in healthy controls (NCO) and hemodialysis
patients at 0, 60 and 300 minutes. Basal levels are significantly elevated
in patients (P < 0.05) and further increased during HD (P < 0.05).
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Fig. 3. Basal (U) and C + P stimulated () T-cell IL 2 release in
healthy control (NCO) and in patients during HD at 0, 30, 60 and 300
minutes, Basal and stimulated IL 2 release is significantly increased at
30 minutes (P < 0.05).
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Fig. 4. Direct effects of dialysis membrane particles on IL 1 and JL 2
release. Abbreviations are: Co, unstimulated; Si, silica; LPS, lipopoly-
sacchande; C, conA; P,PMA; Memb, cytokine release in the presence
of membrane particles. Membrane particles lead to a significantly
increased IL I and IL 2 release (P < 0.05) not different from values
when commonly used stimuli (that is, Si, LPS, C + P and Cresp.) were
added to the cells in vitro.
membranes were added to the cultures (Fig. 4A). Similarly
lymphocytes incubated with cellulose membrane particles pro-
duced significantly more IL 2 activity in comparison to un-
treated cells (Fig. 4B). Therefore contact of mononuclear cells
to dialysis membranes during HD as well as under experimental
conditions results in an increased release of lymphokines.
Discussion
The present study documents normal basal IL 1 production
by cultured monocytes in patients with chronic renal failure as
well as a significant elevation of serum IL 1 levels. IL I is
mainly excreted through the kidneys and thus the increased
serum IL 1 levels together with normal PBMC IL I production
might only reflect the renal impairment. However, onset of
dialysis resulted in a significant increase of monocyte IL 1
production and serum IL 1 levels with maximal levels after 30
minutes and five hours when patients usually were discon-
nected. Thus monocyte dialysis membrane interactions as well
as agents generated during dialysis or bacterial contamination
may account for monocyte activation, which results in an
increased IL 1 production. Since phagocytosis and adherence
of certain particles are potent stimulators of macrophage IL 1
production [19, 201 the contact of monocytes with dialysis
membranes or uptake of inert silicone particles generated
during dialysis [21] may induce IL 1 production. However,
incubation of monocytes from hemodialysis patients in the
presence of silica resulted in a further increase of basal IL 1
production, suggesting that the way of monocyte activation
during HD may differ from the in vitro effect of Silica, that is,
phagocytosis and adherence. Furthermore, direct exposure of
monocytes to cellulose membrane particles stimulated cells to
produce more IL 1, indicating a direct interaction of both
membrane materials with monocytes. Similar findings were
obtained when monocytes in culture were stimulated with
cuprophane membranes (data not shown). However cupro-
phane membranes usually are not used in our HD center.
Complement activation has been shown to occur early during
hemodialysis. However, the transient nature of granulocyto-
penia and leukostasis may be due to down regulation of C5a
receptor expression [22]. Since Ca which is generated through-
out the hemodialysis also stimulates macrophages expressing
receptors for C5a [231 to release IL 1 in vitro [24], generation of
C5a may further contribute to the increased IL 1 production
during hemodialysis. Moreover, increased serum IL 1 levels
during the course of dialysis may account for the normalization
of leukopenia in later stages of hemodialysis, since in vivo
application of IL 1 has been shown to cause a direct release of
neutrophils from the bone marrow [251.
In addition to the enhanced macrophage IL 1 production,
cultured lymphocytes of patients with renal insufficiency in
vitro released significantly more IL 2 during HD when com-
pared to the normal basal values. Addition of potent stimulants
such as Con A and PMA induced a further increase of IL 2
release. However, only at 30 minutes was unstimulated and
stimulated lymphocyte IL 2 production significantly higher than
before HD. Lymphocyte supernatants obtained at later HD
stages may contain more IL 2 inhibiting mediators leading to IL
2 levels within the normal range. As is the case with IL 1,
contact of T lymphocytes with membrane particles under
experimental conditions stimulated cells to release increased
levels of IL 2, suggesting a direct effect of membrane material
on T-cells. Again a similar effect was observed when cellulose
or cuprophane were tested. Moreover IL 1 which is well known
to increase IL 2 production by activated T-lymphocytes [261
may account for additional activation of T-cell IL 2 production.
In culture when lymphocytes were incubated in the presence of
membrane particles IL 1 may be released from a low percentage
(5%) of contaminating monocytes. However, IL I has been
shown to stimulate only activated lymphocytes to produce
more IL 2 [26]. Thus membranes either directly stimulate
lymphocyte IL 2 production or like mitogen they activate
lymphocytes which subsequently in response to IL I release
more IL 2.
Although bacterial endotoxins or complement fragments may
cause enhanced cytokine production, these findings demon-
strate that direct interaction of mononuclear cells with cellulose
membranes during hemodialysis and under experimental con-
dition leads to an increased release of immunoregulatory medi-
ators. The multifaceted biological effects of these factors [6]
may explain some of the pathological findings observed during
hemodialysis such as fever, increased levels of acute phase
proteins, leucocytosis and PGE2 production. In addition
cytokines may be responsible for increased catabolic processes
decreased levels of cations, such as iron and zinc and increased
fibrosis.
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